Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The FlexNav delivery system (DS) features a hydrophilic coating, stability layer, and integrated sheath to facilitate valve deployment in vessel diameters ≥5.0 mm.
Methods: Data were pooled from 2 concurrent prospective, multicenter, premarket studies (PORTICO IDE [n = 147] and FlexNav EU CE Mark [n = 46]) to evaluate the safety and efficacy of the FlexNav DS to deliver the Portico valve in the Global FlexNav study. The primary end point was Valve Academic Research Consortium (VARC)-2 major vascular complication rate at 30 days. These outcomes were compared with those of the commercially available valve arm from the PORTICO IDE study.
Results: The Global FlexNav study enrolled 193 high- or extreme-risk subjects for sugery. The mean age was 84.8 years, and 59.6% were women, with a mean Society of Thoracic Surgeons score of 5.2%. At 1 year, the rate of all-cause mortality was 5.2%, disabling stroke 2.1%, and mild or less paravalvular leak 99.4%. The mean aortic gradient was maintained at 7.4 ± 4.3 mm Hg through 1 year. At 1 year, 96.8% of subjects were classified as New York Heart Association class I or II. A pacemaker was implanted in 15.4% of subjects at 30 days and 18.4% at 1 year. The results of the Portico valve in the Global FlexNav study are comparable with the results from the commercially available valve arm in the PORTICO IDE study.
Conclusion: The FlexNav DS was shown to be safe for the delivery of the Portico valve, which demonstrated sustained treatment benefits at 1 year with low rates of all-cause mortality or disabling stroke, improved heart failure symptoms, and excellent valve performance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307911 | PMC |
| http://dx.doi.org/10.1016/j.jscai.2022.100562 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes Following Minimally Invasive Surgery for Intracerebral Hemorrhage in the AHA Get With The Guidelines-Stroke Registry.
Stroke
June 2025
Yale Center for Brain and Mind Health (G.J.F., S.P., K.N.S.), Yale University School of Medicine, New Haven, CT.
Background: The efficacy of minimally invasive surgery (MIS) in improving outcomes after nontraumatic intracerebral hemorrhage (ICH) remains uncertain, with inconsistent findings from randomized clinical trials. Our objective was to evaluate the real-world impact of MIS on ICH outcomes using a nationally representative cohort.
Methods: We performed a retrospective cohort study of patients with a nontraumatic ICH enrolled in the American Heart Association Get With The Guidelines-Stroke Registry between January 1, 2011, and December 31, 2021.
Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome.
Circulation
July 2024
Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York (G.W.S., R.M.).
Article Synopsis
- * Recent studies have raised concerns about this 12-month regimen, suggesting adjustments based on patients' bleeding or ischemic risks, arguing some may benefit from shorter or longer durations.
- * Several strategies to modify DAPT practices, such as de-escalating to less potent medications or shortening therapy, have shown to reduce bleeding risks without significantly increasing cardiovascular issues, yet the 12-month recommendation remains unchanged in guidelines.
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Circulation
June 2024
TIMI Study Group (S.M.P., Y.M.K., K.I., M.S.S., S.D.W.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Article Synopsis
- * A meta-analysis included 78,607 patients from 11 trials, revealing that SGLT2i reduced MACE by 9%, primarily due to lower rates of cardiovascular death rather than incidents of myocardial infarction or stroke.
- * Results showed consistent benefits from SGLT2i in patients with diabetes, heart failure, and chronic kidney disease, suggesting wide applicability for improving heart-related outcomes among these populations.
Antithrombotic and Statin Prescription After Intracerebral Hemorrhage in the Get With The Guidelines-Stroke Registry.
Stroke
December 2023
Division of Neurocritical Care and Emergency Neurology, Departments of Neurology and Neurosurgery, The Yale Center for Brain and Mind Health (K.N.S.), Yale School of Medicine, New Haven, CT.
Article Synopsis
- Survivors of intracerebral hemorrhage (ICH) have an elevated risk of future ischemic cardiovascular events, but current guidelines do not clearly recommend the use of antithrombotic or statin therapies post-ICH.
- A study analyzed data from the Get With The Guidelines-Stroke registry (2011-2021) to examine patterns of medication prescription at discharge and factors influencing the use of these therapies after ICH.
- Results showed that a small percentage of patients were prescribed antithrombotic medications (10.4%), statins (35.1%), and anticoagulants (5.4%), with higher prescription rates linked to younger age, male sex, and prior medication use for conditions like ischemic vascular
Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.
Circ Cardiovasc Interv
September 2023
Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY (D.L.B.).
Article Synopsis
- Short-term dual antiplatelet therapy (DAPT) for patients with acute coronary syndrome shows potential benefits, including reduced risks of major cardiovascular events and bleeding compared to standard DAPT.
- A systematic review covered 32 randomized controlled trials with nearly 104,000 patients, analyzing various DAPT strategies, including short-term therapy and unguided de-escalation.
- Results indicated that unguided de-escalation reduced major adverse cardiovascular events and showed a better safety profile, making it a strong candidate for treatment protocols over standard approaches.